darunavir has been researched along with cobicistat in 87 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (cobicistat) | Trials (cobicistat) | Recent Studies (post-2010) (cobicistat) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 300 | 75 | 282 |
| Protein | Taxonomy | darunavir (IC50) | cobicistat (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.15 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 9.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 40 (45.98) | 24.3611 |
| 2020's | 47 (54.02) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Deeks, ED | 2 |
| Hillewaert, V; Hoetelmans, RM; Iterbeke, K; Kakuda, TN; Opsomer, M; Petrovic, R; Timmers, M; Van De Casteele, T | 1 |
| Hoetelmans, RM; Kakuda, TN; Neujens, M; Opsomer, M; Petrovic, R; Salih, H; Van De Casteele, T | 1 |
| Crauwels, H; de Smedt, G; Iterbeke, K; Kakuda, TN; Opsomer, M; Tomaka, F; van de Casteele, T; Vanveggel, S | 1 |
| Gauthier, TP; Schafer, JJ; Sherman, EM; Unger, NR; Worley, MV | 1 |
| Avihingsanon, A; Do, T; Putcharoen, O; Ruxrungtham, K | 1 |
| Capetti, A; Cossu, MV; Rizzardini, G | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Asensi-Díez, R; Castaño-Carracedo, MA; Del Rio-Valencia, JC; Muñoz-Castillo, I; Yunquera-Romero, L | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Benmarzouk-Hidalgo, OJ; Espinosa, N; Fernandez-Magdaleno, T; Gutierrez-Valencia, A; Llaves, S; Lopez-Cortes, LF; Viciana, P | 1 |
| Blanco Arévalo, JL | 1 |
| González-Domenech, CM; Palacios, R; Santos, J | 1 |
| Khoo, S; Owen, A; Roberts, O; Siccardi, M | 1 |
| Capetti, A; Cattaneo, D; Clementi, E; Cozzi, V; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Brown, K; Liu, C; Nettles, RE; Patel, M; Patterson-Browning, B; Stewart, L | 1 |
| Amara, A; Boffito, M; Elliot, ER; Else, L; Higgs, C; Khoo, S; Moyle, G; Pagani, N; Schoolmeesters, A | 1 |
| Bartels, H; Battegay, M; Decosterd, L; Marzolini, C | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Fulco, PP; Higginson, RT; Kakadiya, PP | 1 |
| Challenger, E; Clotet, B; Curran, A; Khoo, S; Miranda, C; Moltó, J; Ribera, E; Santos, JR; Valle, M | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| Castilla, JA; Gonzalvo, MC; Hidalgo, C; López-Ruz, MA; López-Zúñiga, MA; Pasquau, J; Rosario, J; Sampedro, A | 1 |
| Clotet, B; Negredo, E | 1 |
| Castagna, A; Lazzarin, A; Spagnuolo, V | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Amara, A; Bisdomini, E; Boffito, M; Cerrone, M; Elliot, ER; Else, L; Khoo, S; Owen, A | 1 |
| Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Castro, Á; Cid, P; Dueñas, C; Garcinuño, MÁ; Grande, C; Lorenzo, JF; Margusino, L; Mena, Á; Quiñones, M; Rodríguez-Osorio, I | 1 |
| Bicer, C; Brown, K; Crauwels, HM; Osiyemi, O; Zorrilla, C | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Angioni, G; Bonfanti, P; Calza, L; Cascio, A; De Socio, GV; Dentone, C; Di Biagio, A; Madeddu, G; Maggi, P; Menzaghi, B; Pellicanò, GF; Ricci, E; Squillace, N; Taramasso, L; Valsecchi, L | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| López-Ruz, MÁ; Rosales-Castillo, A | 1 |
| Alejos, B; Boix, V; Garcia-Fraile, L; Gonzalez-Cordon, A; Gonzalez-Domenech, CM; Gutierrez, M; Knobel, H; Lozano, F; Martin-Carbonero, L; Martinez, E; Montero, M; Moreno, A; Negredo, E; Ocampo, A; Payeras, A; Perez-Elias, MJ; Sanz, J; Torralba, M | 1 |
| Brizzi, MB; Chiampas, TD; Novak, RM | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Das, M; Kearney, BP; Ling, KH; Majeed, SR; West, S | 1 |
| Bailey, AC; Mackie, N; Muir, D; Ring, K | 1 |
| Antinori, A; Bonora, S; Castelli, F; Cattelan, AM; Cauda, R; Celesia, BM; Cossu, MV; d'Arminio Monforte, A; Gianotti, N; Gori, A; Mancusi, D; Manzillo, E; Maserati, R; Menzaghi, B; Orofino, G; Ripamonti, D; Rucci, F; Rusconi, S; Santantonio, TA; Savinelli, S; Sterrantino, G; Stingone, C; Termini, R; Uglietti, A; Vergori, A | 1 |
| Castagna, A; Comi, L; Di Filippo, E; Fumagalli, L; Galli, L; Gianotti, N; Maggiolo, F; Nozza, S; Rizzi, M; Valenti, D | 2 |
| Burger, DM; Calmy, A; Marzolini, C | 1 |
| Cravedi, P; Degli Antoni, A; Delsante, M; Fiaccadori, E; Gandolfini, I; Maggiore, U; Manenti, L; Peruzzi, L; Riella, LV; Zaza, G | 1 |
| Antinori, A; Aprea, L; Castagna, A; Cattelan, A; Cossu, MV; D'Ettore, G; Di Cristo, V; Ferrara, S; Focà, E; Gori, A; Locatelli, ME; Madeddu, G; Mancusi, D; Menzaghi, B; Orofino, G; Pontali, E; Rossetti, B; Rucci, F; Scerbo, P; Squillace, N; Sterrantino, G; Termini, R; Uglietti, A; Valenti, D | 1 |
| Iselin, HU; Piunno, A; Spezzani, V | 1 |
| Bagalà, A; Bartiromo, M; Bartoloni, A; Borchi, B; Botta, A; Bresci, S; Cavallo, A; Cirami, C; Cutruzzulà, R; Larti, A; Lugli, G; Tilli, M; Vaglio, A; Xhaferi, B | 1 |
| Anselmi, E; Cavanna, L; Citterio, C; Codeluppi, M; Stroppa, EM; Toscani, I; Zaffignani, E | 1 |
| Chen, C; Chen, M; Cheng, C; Chi, Y; Hu, Z; Huang, S; Jiao, D; Liang, C; Liu, Y; Lv, Y; Sun, W; Wei, H; Yi, Y; Zhang, X | 1 |
| Finn, AV; Guagliumi, G; Pellegrini, D; Pescetelli, I; Sonzogni, A | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Belkhir, L; Elens, L; Haufroid, V; Stillemans, G; Vandercam, B; Vincent, A | 1 |
| Chen, F; Chen, Y; Fang, Q; Hu, S; Jiang, J; Liang, T; Lu, S; Sheng, J; Wei, N; Wu, L; Zheng, S; Zhou, J | 1 |
| Choi, EY; Choi, SH; Kim, EJ; Kim, Y; Kwon, YS; Lee, J; Lee, SY; Park, JS | 1 |
| Emanuela, C; Francesco, L; Giorgia, G; Pasquale, N; Roberto, P; Sara, D | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Devi Singh, V; Kumar Singh, V | 1 |
| Chinen, M; Hayashida, T; Hirano, A; Kobayashi, M; Masuda, J; Watanabe, K | 1 |
| Alejos, B; Boix, V; Crespo, M; De La Fuente Moral, S; De La Torre Lima, J; De Los Santos Gil, I; Galindo, MJ; Gutierrez, MM; Lozano, F; Martinez, E; Montero-Alonso, M; Palacios, R; Payeras Cifre, A; Perez Elias, MJ; Ribera, E; Sanz, J | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Best, BM; Burchett, S; Capparelli, EV; Chakhtoura, N; Denson, K; Febo, IL; George, K; Mirochnick, M; Momper, JD; Paul, ME; Rungruengthanakit, K; Scott, GB; Shapiro, DE; Smith, E; Stek, A; Wang, J; Yang, DZ | 1 |
| Boix, V; Dash, PK | 1 |
| Chao, CM; Hsueh, PR; Lai, CC | 1 |
| Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E | 1 |
| Andena, AM; Cattadori, E; Cavanna, L; Citterio, C; Codeluppi, M; Cremona, G; Gubbelini, M; Maniscalco, P; Muroni, L; Muroni, M; Nolli, M; Nunzio, CD; Pedrazzini, G; Schiavo, R | 1 |
| Abu Khattab, M; Al Maslamani, M; Al Soub, H; Al-Khal, A; Alibrahim, R; Elmekaty, EZI; Elsayed, A; Eltaib, S; Hassanin, R; Mohamed Ibrahim, MI; Rustom, F | 1 |
| Bungau, SG; Marin, RC; Moleriu, LC; Streinu-Cercel, A | 1 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Chen, W; Deng, M; Lin, J; Lv, X; Shen, L; Shen, P; Zhang, Y | 1 |
| Cuéllar-Monreal, MJ; Monte-Boquet, E; Montero, M; Pérez-Huertas, P; Poveda-Andrés, JL; Salavert, M; Solana-Altabella, A | 1 |
| Bungau, SG; Marin, RC; Moleriu, RD; Negru, PA; Radu, AF; Tit, DM | 1 |
| Anderson, D; Bushen, J; Cai, J; Dunn, K; Luo, D; Simonson, RB | 1 |
| Antinori, S; Cattaneo, D; Gervasoni, C; Gori, A; Micheli, V; Pagano, S | 1 |
| Ariyawansa, J; Palmer, M; Van Hemelryck, S; Van Landuyt, E; Vanveggel, S | 1 |
| Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
| Adeojo, L; Brooks, KM; Bunn, HT; George, JM; Kovacs, JA; Kumar, P; Pau, AK; Peloquin, CA; Swaim, D | 1 |
15 review(s) available for darunavir and cobicistat
| Article | Year |
|---|---|
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
Darunavir/cobicistat once daily for the treatment of HIV.
Topics: Clinical Trials as Topic; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir; Treatment Outcome | 2015 |
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Quinolones | 2015 |
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Topics: Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Combinations; Drug Interactions; Food-Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Risk Factors; Treatment Outcome | 2015 |
Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.
Topics: Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans | 2015 |
[Darunavir as initial therapy for human immunodeficiency virus infection and as a strategy for switching regimen not motivated by virological failure].
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; HIV Infections; Humans; Ritonavir; Viral Load | 2016 |
[Pharmacological aspects of darunavir/cobicistat].
Topics: Cobicistat; Darunavir; Drug Combinations; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Current treatment of COVID-19 in renal patients: hope or hype?
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Drug Combinations; Humans; Kidney; Lopinavir; Pandemics; Pneumonia, Viral; Pyrazines; Renal Insufficiency, Chronic; Renal Replacement Therapy; Ritonavir | 2020 |
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Carbamates; Cobicistat; COVID-19 Drug Treatment; Darunavir; Dibenzothiepins; Drug Combinations; Drug Therapy, Combination; Humans; Imidazoles; Indoles; Iran; Lopinavir; Morpholines; Pyrazines; Pyridones; Pyrrolidines; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Triazines; Valine | 2021 |
24 trial(s) available for darunavir and cobicistat
| Article | Year |
|---|---|
Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Topics: Adult; Biological Availability; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Combinations; Female; Healthy Volunteers; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Thiazoles; Young Adult | 2014 |
Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Carbamates; Cobicistat; Darunavir; Drug Combinations; Drug Monitoring; Female; Food; Healthy Volunteers; Humans; Male; Middle Aged; Sulfonamides; Therapeutic Equivalency; Thiazoles; Young Adult | 2014 |
Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Synergism; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Treatment Outcome; Young Adult | 2017 |
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Female; Half-Life; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Saliva; Young Adult | 2017 |
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Ritonavir; Tandem Mass Spectrometry | 2017 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr
Topics: Adult; Cobicistat; Darunavir; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Tenofovir; Treatment Outcome; Viral Load | 2018 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Young Adult | 2018 |
Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Young Adult | 2019 |
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2019 |
Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
Topics: Adult; Cobicistat; Darunavir; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal Age; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Treatment Outcome | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
Topics: Adolescent; Adult; Androstenes; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Cobicistat; Cohort Studies; Contraceptives, Oral, Hormonal; Darunavir; Drug Interactions; Ethinyl Estradiol; Female; Half-Life; Humans; Mineralocorticoid Receptor Antagonists; Young Adult | 2019 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; Treatment Outcome; Viral Load | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
Topics: Anti-HIV Agents; Child; Cobicistat; Darunavir; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Placenta; Postpartum Period; Pregnancy; Prospective Studies | 2021 |
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Topics: Adult; Cobicistat; Darunavir; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; RNA; United States; Viral Load | 2021 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans | 2023 |
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tablets; Therapeutic Equivalency | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
48 other study(ies) available for darunavir and cobicistat
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
[Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
Topics: Adult; Cobicistat; Darunavir; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Prospective Studies; Ritonavir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Young Adult | 2017 |
Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
Topics: Antirheumatic Agents; Antitubercular Agents; Cells, Cultured; Cobicistat; Darunavir; Drug Interactions; Drug Therapy, Combination; Hepatocytes; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Mycobacterium tuberculosis; Rifampin; Ritonavir; Tuberculosis, Pulmonary | 2017 |
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
Topics: Anti-HIV Agents; Cobicistat; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir | 2017 |
Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.
Topics: Aged; Anti-HIV Agents; Cobicistat; Dabigatran; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Ritonavir | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Semen; Semen Analysis; Viral Load | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
Topics: Adult; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2018 |
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA).
Topics: Adult; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Viral Load | 2019 |
Cushing's syndrome due to interaction between topical betamethasone dipropionate and darunavir/cobicistat.
Topics: Betamethasone; Cobicistat; Cushing Syndrome; Darunavir; Humans | 2020 |
Factors associated with the number of drugs in darunavir/cobicistat regimens.
Topics: Adult; Age Factors; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Spain; Viral Load | 2020 |
Simplification of ART in a patient living with multidrug resistant HIV-1: A case report using twice daily cobicistat and darunavir.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Treatment Outcome | 2019 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
HIV-1 superinfection in a patient with known HIV-2 - A case report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Male; Middle Aged; Superinfection; Tenofovir; Treatment Outcome | 2020 |
Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Viral Load | 2020 |
Cobicistat: A case of mislabelled drug-drug interaction risk?
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Interactions; Drug Labeling; HIV Infections; Humans; Pharmaceutical Preparations | 2020 |
COVID-19 in kidney transplant recipients.
Topics: Aged; Betacoronavirus; Cobicistat; Colchicine; Coronavirus Infections; COVID-19; Cytokines; Darunavir; Drug Combinations; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lopinavir; Male; Middle Aged; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tacrolimus; Transplant Recipients; Treatment Outcome | 2020 |
Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression.
Topics: Adult; Anti-HIV Agents; Cobicistat; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Male; Middle Aged; Patient Reported Outcome Measures; Patient Satisfaction; Prospective Studies; Surveys and Questionnaires | 2020 |
Benign COVID-19 in an immunocompromised cancer patient - the case of a married couple.
Topics: Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Breast Neoplasms; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Critical Care; Darunavir; Dyspnea; Emergency Service, Hospital; Female; Fever; Humans; Hydroxychloroquine; Immunocompetence; Immunocompromised Host; Male; Middle Aged; Neoplasm Recurrence, Local; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spouses; Treatment Outcome | 2020 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deprescriptions; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fatigue; Female; Glucocorticoids; Graft Rejection; Humans; Hydroxychloroquine; Immunocompromised Host; Immunosuppressive Agents; Interleukin-10; Interleukin-1beta; Interleukin-6; Interleukin-8; Kidney Diseases, Cystic; Kidney Failure, Chronic; Kidney Transplantation; Leber Congenital Amaurosis; Lopinavir; Methylprednisolone; Optic Atrophies, Hereditary; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tacrolimus | 2020 |
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Hydroxychloroquine; Italy; Lopinavir; Male; Methylprednisolone; Middle Aged; Neoplasms; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
A special symptom of olfactory dysfunction in coronavirus disease 2019: report of three cases.
Topics: Adolescent; Adult; Antiviral Agents; Betacoronavirus; China; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Female; Humans; Indoles; Male; Methylprednisolone; Olfaction Disorders; Pandemics; Pneumonia, Viral; SARS-CoV-2; Taste Disorders; Treatment Outcome; Vitamin B 12 | 2020 |
Microthrombi and ST-Segment-Elevation Myocardial Infarction in COVID-19.
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Cobicistat; Coronavirus Infections; COVID-19; Darunavir; Electrocardiography; Female; Humans; Hypokinesia; Hypotension; International Normalized Ratio; Myocardium; Nasopharynx; Pandemics; Platelet Count; Pneumonia, Viral; SARS-CoV-2; ST Elevation Myocardial Infarction; Thrombosis; Troponin I; Ventricular Dysfunction, Left | 2020 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations.
Topics: Cobicistat; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir | 2021 |
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.
Topics: Antibodies, Viral; Antipsychotic Agents; Antiviral Agents; Betacoronavirus; Bipolar Disorder; Brain; Chest Pain; China; Clinical Laboratory Techniques; Cobicistat; Coronavirus Infections; COVID-19; COVID-19 Testing; Darunavir; Dyspnea; Fever; Glucocorticoids; Humans; Indoles; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Olanzapine; Pandemics; Pharyngitis; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2 | 2020 |
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.
Topics: Adult; Anti-HIV Agents; Betacoronavirus; Case-Control Studies; Cobicistat; Coronavirus Infections; COVID-19; Critical Illness; Darunavir; Female; HIV Protease Inhibitors; Humans; Intensive Care Units; Male; Middle Aged; Pandemics; Pneumonia, Viral; Republic of Korea; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2020 |
Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation.
Topics: Cobicistat; Darunavir; HIV Infections; Humans; Spectrophotometry; Tablets | 2021 |
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Pyridones; Renal Dialysis; Triazoles | 2021 |
Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Darunavir; Glomerular Filtration Rate; HIV Infections; Humans; Retrospective Studies | 2021 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy | 2021 |
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Topics: Aged; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Cobicistat; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
COVID-19 Outbreak in Italy: Report on the First 124 Consecutive Patients Treated at Home.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cobicistat; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Darunavir; Disease Outbreaks; Drug Combinations; Female; Home Care Services; Hospitalization; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Telemedicine; Young Adult | 2021 |
Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): A multicenter observational study.
Topics: Adult; Cobicistat; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Ritonavir; Treatment Outcome | 2022 |
Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA; Romania; Viral Load | 2022 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Epidemiology, diagnosis and treatment of early COVID-19 patients in Jiaxing City, Zhejiang Province, China, January to March 2020.
Topics: China; Cities; Cobicistat; COVID-19; Darunavir; Female; Humans; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir | 2022 |
Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Retrospective Studies; Ritonavir; Viral Load | 2022 |
Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child, Preschool; Cobicistat; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Retrospective Studies; Ritonavir; Romania; Viral Load | 2023 |
Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat.
Topics: Anti-HIV Agents; Cobicistat; Darunavir; HIV Infections; Humans; Pyridones | 2023 |
Pharmacokinetics, Safety, and Tolerability of Once-Daily Darunavir With Cobicistat and Weekly Isoniazid/Rifapentine.
Topics: Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; HIV Infections; Humans; Isoniazid | 2023 |